Pages that link to "Q27674734"
Jump to navigation
Jump to search
The following pages link to Accelerated disassembly of IgE–receptor complexes by a disruptive macromolecular inhibitor (Q27674734):
Displaying 33 items.
- Design, construction, and characterization of a second-generation DARPin library with reduced hydrophobicity (Q27679138) (← links)
- Human immunoglobulin E flexes between acutely bent and extended conformations. (Q27682236) (← links)
- Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. (Q30855879) (← links)
- Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells (Q33850604) (← links)
- Novel targeted therapies for eosinophil-associated diseases and allergy (Q34444620) (← links)
- The Potential of Anti-IgE in Food Allergy Therapy (Q34532292) (← links)
- "Auto-anti-IgE": naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation. (Q34647874) (← links)
- Development of small molecules to target the IgE:FcεRI protein-protein interaction in allergies (Q34898939) (← links)
- Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. (Q36919753) (← links)
- Facilitated Dissociation of a Nucleoid Protein from the Bacterial Chromosome (Q36950827) (← links)
- Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases (Q36983081) (← links)
- IgE-Related Chronic Diseases and Anti-IgE-Based Treatments (Q37554168) (← links)
- HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation (Q38181859) (← links)
- An overview of the effects of anti-IgE therapies (Q38252958) (← links)
- The future of biologics: applications for food allergy (Q38348057) (← links)
- Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. (Q38615378) (← links)
- Looking forward to new targeted treatments for chronic spontaneous urticaria (Q38771632) (← links)
- From IgE to Omalizumab (Q38793428) (← links)
- Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells. (Q40090566) (← links)
- SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE. (Q42150934) (← links)
- Sensing and responding to allergic response cytokines through a genetically encoded circuit (Q42645824) (← links)
- Thermal sensitivity and flexibility of the Cε3 domains in immunoglobulin E. (Q42650125) (← links)
- Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction. (Q47203998) (← links)
- Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels (Q47943679) (← links)
- IL-3 but not monomeric IgE regulates FcεRI levels and cell survival in primary human basophils. (Q55331784) (← links)
- Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody (Q60628285) (← links)
- Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease (Q64241041) (← links)
- Effects of electrostatic interactions on ligand dissociation kinetics (Q88082238) (← links)
- IgE Antibodies: From Structure to Function and Clinical Translation (Q90211875) (← links)
- Tailoring the component of protein corona via simple chemistry (Q90495356) (← links)
- How do DNA-bound proteins leave their binding sites? The role of facilitated dissociation (Q90502895) (← links)
- IgE Glycosylation in Health and Disease (Q92027568) (← links)
- The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab (Q92491308) (← links)